Stevens First Principles Investment Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-200	Closed	-$19K	–	199
2015 Q3	$19K	Sell	200 -200	-50%	-$22.9K	0.02%	152
2015 Q2	$41K	Buy	+400	New	+$31.1K	0.03%	142

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stevens First Principles Investment Advisors's RARE Position: Q4 2015 in Review

Stevens First Principles Investment Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2015, closing a stake of 200 shares — an estimated $19K sold.

Stevens First Principles Investment Advisors first reported a position in RARE in Q2 2015 and held it in 2 quarters. The position peaked at $41K in Q2 2015. 171 funds tracked by Wall St. Rank hold RARE as of Q4 2015.

Stevens First Principles Investment Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q4 2015 after selling out during the quarter.
Stevens First Principles Investment Advisors sold 200 Ultragenyx Pharmaceutical shares in Q4 2015, an estimated $19K.
Stevens First Principles Investment Advisors first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 2 quarters.
Stevens First Principles Investment Advisors's Ultragenyx Pharmaceutical position peaked at $41K in Q2 2015.
171 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2015.

Based on Stevens First Principles Investment Advisors's 13F filing for Q4 2015, filed 29 Jan 2016.